Effects of gender on response to treatment with rivastigmine in mild cognitive impairment: A post hoc statistical modeling approach

Petersen, 2001, Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology, Neurology, 56, 1133, 10.1212/WNL.56.9.1133 Bäckman, 2005, Cognitive impairment in preclinical Alzheimer's disease: A meta-analysis, Neuropsychology, 19, 520, 10.1037/0894-4105.19.4.520 Palmer, 2002, Differential evolution of cognitive impairment in nondemented older persons: Results from the Kungsholmen Project, Am J Psychiatry, 159, 142, 10.1176/appi.ajp.159.3.436 Fleisher, 2005, Sex, apoli-poprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment, Arch Neurol., 62, 953, 10.1001/archneur.62.6.953 Feldman, 2007, Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: The InDDEx study [published correction appears in Lancet Neurol. 2007;6:849], Lancet Neurol., 6, 501, 10.1016/S1474-4422(07)70109-6 Lane, 2008, Synergistic effect of apolipoprotein E epsilon4 and butyryl-cholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease, Pharmacogenet Genomics, 18, 289, 10.1097/FPC.0b013e3282f63f29 Rocca, 1991, Frequency and distribution of Alzheimer's disease in Europe: A collaborative study of 1980–1990 prevalence findings, Ann Neurol., 30, 381, 10.1002/ana.410300310 McGonigal, 1993, Epidemiology of Alzheimer's presenile dementia in Scotland, 1974–88, BMJ, 306, 680, 10.1136/bmj.306.6879.680 Jorm, 1998, The incidence of dementia: A meta-analysis, Neurology, 51, 728, 10.1212/WNL.51.3.728 Tervo, 2004, Incidence and risk factors for mild cognitive impairment: A population-based three-year follow-up study of cognitively healthy elderly subjects, Dement Geriatr Cogn Disord, 17, 196, 10.1159/000076356 Hänninen, 2002, Prevalence of mild cognitive impairment: A population-based study in elderly subjects, Acta Neurol Scand, 106, 148, 10.1034/j.1600-0404.2002.01225.x Waldemar, 2007, Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline, Eur J Neurol., 14, e1, 10.1111/j.1468-1331.2006.01605.x Petersen, 2005, Vitamin E and donepezil for the treatment of mild cognitive impairment, N Engl J Med., 352, 2379, 10.1056/NEJMoa050151 Winblad, 2008, Safety and efficacy of galantamine in subjects with mild cognitive impairment, Neurology, 70, 2024, 10.1212/01.wnl.0000303815.69777.26 Gauthier, 2006, Aggressive course of disease in dementia, Alzheimer's Dementia, 2, 210, 10.1016/j.jalz.2006.03.002 Styner, 2002, Multi-site validation of image analysis methods-assessing intra and inter-site variability, 4684, 278 Rust, 1993, Mutagenically separated PCR (MS-PCR): A highly specific one step procedure for easy mutation detection, Nucleic Acids Res., 21, 3623, 10.1093/nar/21.16.3623 Barnes, 2005, Sex differences in the clinical manifestations of Alzheimer disease pathology, Arch Gen Psychiatry, 62, 685, 10.1001/archpsyc.62.6.685 Miyashita, 2007, Genetic association of CTNNA3 with late-onset Alzheimer's disease in females, Hum Mol Genet., 16, 2854, 10.1093/hmg/ddm244 Kovalev, 2007, Texture anisotropy of the brain's white matter as revealed by anatomical MRI, IEEE Trans Med Imaging, 26, 678, 10.1109/TMI.2007.895481 Hsu, 2008, Gender differences and age-related white matter changes of the human brain: A diffusion tensor imaging study, Neuroimage, 39, 566, 10.1016/j.neuroimage.2007.09.017 Yue, 2005, Brain estrogen deficiency accelerates Abeta plaque formation in an Alzheimer's disease animal model, Proc Natl Acad Sci USA, 102, 19198, 10.1073/pnas.0505203102 Manly, 2000, Endogenous estrogen levels and Alzheimer's disease among postmenopausal women, Neurology, 54, 833, 10.1212/WNL.54.4.833 Resnick, 2002, Hormone therapy and risk of Alzheimer disease: A critical time, JAMA, 288, 2170, 10.1001/jama.288.17.2170 Agid, 1998, Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type, Curr Ther Res Clin Exp., 59, 837, 10.1016/S0011-393X(98)85048-0 Anand, 2000, Dose-response effect of rivastigmine in the treatment of Alzheimer's disease, Int J Geriatr Psychopharmacol, 2, 68 Corey-Bloom, 1998, A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease, Int J Geriatr Psychopharmacol, 1, 55